Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK.
Tanis
Steven P
SP
Global Research and Development, Pfizer Inc., San Diego, CA 92121, USA. sptanis@sbcglobal.net
Plewe
Michael B
MB
Johnson
Ted W
TW
Butler
Scott L
SL
Dalvie
Deepak
D
DeLisle
Dorothy
D
Dress
Klaus R
KR
Hu
Qiyue
Q
Huang
Buwen
B
Kuehler
Jon E
JE
Kuki
Atsuo
A
Liu
Wen
W
Peng
Qinghai
Q
Smith
Graham L
GL
Solowiej
Jim
J
Tran
Khanh T
KT
Wang
Hai
H
Yang
Anle
A
Yin
Chunfeng
C
Yu
Xiaoming
X
Zhang
Junhu
J
Zhu
Huichun
H
D000284:Administration, Oral; D000818:Animals; D004285:Dogs; D019427:HIV Integrase / Q000737:chemistry* / Q000378:metabolism; D019428:HIV Integrase Inhibitors / Q000737:chemistry* / Q000493:pharmacokinetics / Q000633:toxicity; D015497:HIV-1 / Q000201:enzymology*; D006207:Half-Life; D022781:Hepatocytes / Q000187:drug effects; D006801:Humans; D006877:Hydroxamic Acids / Q000737:chemistry* / Q000493:pharmacokinetics / Q000633:toxicity; D007211:Indoles / Q000737:chemistry*; D013329:Structure-Activity Relationship
D019428:HIV Integrase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; C030374:indole; D019427:HIV Integrase; C514801:p31 integrase protein, Human immunodeficiency virus 1